Published • loading... • Updated
Biosimilars cut into Humira sales and offer savings on costly medicines
Summary by Market Business News
Read with caution - this story is only being covered by one news source that has a ‘low factuality’ rating, which means the outlet has a history of poor reporting practices. Learn more about factuality ratings here.1 Articles
1 Articles
Biosimilars cut into Humira sales and offer savings on costly medicines
AbbVie's US Humira revenue fell 47% to $425 million in the second quarter of 2026, illustrating the pressure biosimilar competition can place on a leading medicine. For healthcare systems, that competition offers a route to lower spending, although savings depend on which products reach the market and how widely they are used.
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center1Last UpdatedBias Distribution100% Center
Bias Distribution
- 100% of the sources are Center
100% Center
C 100%
Factuality
To view factuality data please Upgrade to Premium
